MISSISSAUGA, ON--(Marketwired - December 21, 2016) - MedX Health Corp. ("MedX") (TSX VENTURE: MDX) announced today that it has appointed Scott Naughton, Managing Director, US operations. Mr. Naughton has participated in the Senior Management of several US-based medical device and medical service start-ups. He has held COO positions within large and small medical practices. He will also join MedX's Advisory Board, which the company plans to expand with Mr. Naughton's assistance.

Mr. Naughton is the Founder of Naughton Brain Trust, based in Pennsylvania, which specializes in assembling specific, targeted intellects and implementing protocols to resolve difficult short-term healthcare projects. In addition, he has been very successful in the start-up and technology sectors.

"We are thrilled that Scott is joining our team and will be our point person in the US. Having someone of his caliber and expertise on the ground in the US is extremely important to help grow our business globally," said Robert von der Porten, President and CEO of MedX. "Scott is highly respected and has developed important and strong relationships in the dermatology, medical and technology sectors, which we believe will help MedX grow market share," Mr. von der Porten added.

"I am very excited to be a member of the MedX team. With skin cancer being a leading cause of death not just in North America but around the world, MedX's patented technology will provide relief and offer hope to potentially millions of people. I believe MedX is a game-changer in the field of cancer detection," Mr. Naughton said.

About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.